MAIA presents THIO-101 Phase 2 poster at AACR-NCI-EORTC conference on Oct 24, 2025

MAIA Biotechnology, Inc.

Poster on Ateganosine (THIO) + ICI in advanced NSCLC patients resistant to prior ICI and chemotherapy.
Presented at AACR-NCI-EORTC Molecular Targets Conference in Boston.
No specific efficacy or safety data disclosed in the 8-K filing.
Company provided forward-looking statements caution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.